Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05401279
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Heath Skinner
- Target Recruit Count
- 150
- Registration Number
- NCT05388773
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
A Trial of GFH018 and Toripalimab in Combination with Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
- Conditions
- Interventions
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT05386888
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 225
- Registration Number
- NCT05382338
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Kaiser Permanente-Oakland, Oakland, California, United States
🇺🇸State University of New York Upstate Medical University, Syracuse, New York, United States
Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Krzysztof Misiukiewicz
- Target Recruit Count
- 24
- Registration Number
- NCT05376553
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Pembrolizumab Plus Olaparib in LA-HNSCC
- Conditions
- Interventions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT05366166
- Locations
- 🇺🇸
UNC Lineberger, Chapel Hill, North Carolina, United States
🇺🇸University of Louisville, Brown Cancer Center, Louisville, Kentucky, United States
🇺🇸Medical University of South Carolina (MUSC), Charleston, South Carolina, United States
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 422
- Registration Number
- NCT05357846
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
- Conditions
- Interventions
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2023-12-14
- Target Recruit Count
- 110
- Registration Number
- NCT05351788
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 264
- Registration Number
- NCT05352321
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 480
- Registration Number
- NCT05342194
- Locations
- 🇨🇳
Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.